Skip to content
2000
Volume 24, Issue 6
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Although there have been significant advancements in cancer treatment, resistance and recurrence in patients make it one of the leading causes of death worldwide. 5-fluorouracil (5-FU), an antimetabolite agent, is widely used in treating a broad range of human malignancies. The cytotoxic effects of 5-FU are mediated by the inhibition of thymidylate synthase (TYMS/TS), resulting in the suppression of essential biosynthetic activity, as well as the misincorporation of its metabolites into RNA and DNA. Despite its huge benefits in cancer therapy, the application of 5-FU in the clinic is restricted due to the occurrence of drug resistance. MicroRNAs (miRNAs) are small, non-coding RNAs that act as negative regulators in many gene expression processes. Research has shown that changes in miRNA play a role in cancer progression and drug resistance. This review examines the role of miRNAs in 5-FU drug resistance in cancers.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557523666230825144150
2024-04-01
2025-09-07
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557523666230825144150
Loading

  • Article Type:
    Review Article
Keyword(s): 5-FU; apoptosis; cancer treatment; chemosensitivity; Drug resistance; miRNAs
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test